## CLAIMS

1. Use of an attenuated mutant strain of Salmonella comprising at least one copy of a recombinant DNA molecule comprising an expression cassette encoding Mesothelin (MSLN) in the manufacture of a vaccine for cancer immunotherapy .

2. The use of claim 1, wherein the attenuated mutant strain of Salmonella is Salmonella typhi Ty21a.

3. The use of claim 1 or 2, wherein the expression cassette is a eukaryotic expression cassette.

4. The use of any one of claims 1 to 3, wherein MSLN is human MSLN having the amino acid sequence as found in SEQ ID NO 1.

5. The use of claim 3 or 4, wherein the recombinant DNA molecule comprises the kanamycin antibiotic resistance gene, the pMB1 ori, and a eukaryotic expression cassette encoding human MSLN under the control of a CMV promoter, wherein human MSLN has the nucleic acid sequence as found in SEQ ID NO 2.

6. The use of any one of the preceding claims, wherein cancer immunotherapy further comprises administration of one or more further attenuated mutant strain(s) of Salmonella comprising at least one copy of a recombinant DNA molecule comprising an expression cassette encoding a tumor antigen and/or a tumor stroma antigen.

7. The use of claim 6, wherein said one or more further attenuated mutant strain(s) of Salmonella comprise(s) an attenuated mutant strain of Salmonella encoding human VEGFR-2 and/or human Wilms' Tumor Protein (WT1).

8. The use of claims 6 or 7, wherein the attenuated mutant strain of Salmonella is to be co-administered with said one or more further attenuated mutant strain(s) of Salmonella.

9. The use of any one of claims 1 to 8, wherein cancer immunotherapy is to be accompanied by chemotherapy, radiotherapy or biological cancer therapy.

10. The use of any one of claims 1 to 9, wherein the attenuated mutant strain of Salmonella is to be administered orally.

11. The use of any one of claims 1 to 10, wherein the cancer is selected from mesotheliomas, ovarian and pancreatic cancers, squamous cell carcinomas of the cervix, head and neck, vulva, lung and esophagus, lung adenocarcinomas, endometrial carcinomas, biphasic synovial sarcomas, desmoplastic small round cell tumors and gastric adenocarcinomas.

12. The use of any one of claims 1 to 11, wherein the single dose comprises from $10^5$ to $10^{11}$ colony forming units (CFU).

13. The use of any one of claims 1 to 12 for use in individualized cancer immunotherapy comprising the step of assessing the MSLN expression pattern and/or the pre-immune response against MSLN of a patient.